Navigation Links
Orion Pharma Selects ChemDiv as A Partner in Drug Discovery Services
Date:11/30/2007

SAN DIEGO, Nov. 30 /PRNewswire/ -- ChemDiv, Inc. and Orion Pharma today announced that Orion has chosen ChemDiv as a discovery partner in small molecule therapeutics for Orion's priority targets.

Under the terms of the agreement, ChemDiv will deploy the Discovery outSource(TM) platform for Orion's discovery program, including the world's largest commercially available chemical library, proprietary rational design, assay development, and bioscreening. ChemDiv will screen rationally designed chemical libraries against Orion's proprietary targets, and Orion will select hit series for subsequent lead optimization. Financial terms and identity of drug targets were not disclosed. The agreement provides options for expanding the discovery partnership.

"I am very satisfied with the commitment and exchange of information in our joint effort. We have a good basis for success," said Dr. Ari Koivisto, Orion's contact person in the collaboration. "Our partnership with ChemDiv complements our in-house discovery effort in this particular project," stated Dr. Antti Haapalinna, Director of Nonclinical R&D, Orion Pharma, Orion Corporation.

"We are delighted to offer discovery services to Orion Pharma in this partnership. We are especially pleased with the constructive dialog with Orion R&D, based on our mutual understanding and shared goals. Based on ChemDiv's diligence and track record, we are confident of success and look forward to expansion of this collaboration in the near future," commented Nikolay Savchuk, President and CEO of ChemDiv, Inc.

About Orion Corporation

Orion Corporation (OMX: ORNAV, ORNBV) is one of the leading pharmaceutical companies in the northern Europe. Orion develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Pharmaceuticals generate about 95% of the Group's net sales, of which proprietary patented pharmaceutical innovations contribute a considerable part. The core therapy areas in Orion's product and research strategy are central nervous system disorders, cardiology and critical care, urology and oncology. Stalevo(R) and Comtess(R) / Comtan(R), treatments originated by Orion for Parkinson 's disease, are the largest products by sales in Orion's portfolio. For additional information, please visit http://www.orion.fi.

About ChemDiv, Inc.

ChemDiv (http://www.chemdiv.com) is a global chemistry-driven contract research organization focused on identifying and delivering pre-clinical opportunities and advanced R&D services for the development of treatments for life-threatening diseases. For over 17 years, ChemDiv has provided its Discovery outSource(TM) solutions to life science partners, including medicinal and synthetic chemistry, pre-clinical development, screening libraries, and global logistics. ChemDiv's international research team encompasses 550 chemists and biologists in San Diego and Moscow based R&D centers.


'/>"/>
SOURCE ChemDiv, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after ... Travel Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run ... 420-page book measures almost a metre across when open, weighs in at more than ...
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... 2017 , ... The Smart Machine Age is here, and it’s disrupting everything. ... of all jobs in the United States may be taken over by technology in ... aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will belong ...
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the Cowen and Company 37 th ... Place on Tuesday, March 7, 2017 at 11:20 a.m. ... the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
Breaking Medicine Technology: